How efficient logistics can change the lives of rare disease patients
Dr. Danial Arkwell, Head of Global Key Accounts, Pharma, at Envirotainer, highlights the vital role of efficient logistics in getting orphan drugs to patients in desperate need.
There are approximately 8,000 rare diseases in the...
£25m funding for future vaccine development
Three ambitious research projects designed to build our understanding of viruses and how the immune system reacts to different challenges will share £25 million in new funding from UK Research and Innovation (UKRI).
Tackling Infections...
Scientists create tailored drug for aggressive breast cancer
Scientists have used breast cancer cells’ weakness against themselves by linking a tumour-selective antibody with a cell-killing drug to destroy hard-to-treat tumours.
The research, published in Clinical Cancer Research by a team from King’s College...
Breakthrough in creating cyclic peptide opens the way for new antibiotics
A discovery by scientists at King’s College London could speed up efforts to produce new antibiotics in the fight against antimicrobial resistance.
In a paper published in the Journal of the American Chemical Society, scientists...
Life-saving cancer drug takes a major step closer to patient care
A new drug candidate for hard-to-treat cancers, discovered at the University of Edinburgh and licensed by biopharmaceutical company Nuvectis Pharma, Inc. (“Nuvectis” or “Company”), can now begin clinical trials as announced by Nuvectis.
The compound,...
Breaking new ground in antibiotic research with neutrons
Dr Luke Clifton, Instrument Scientist at ISIS Neutron and Muon Source, explains how neutrons have emerged as a highly effective tool in the fight against AMR.
Antimicrobial resistance (AMR) has been one of the biggest...
Enzyme discovery paves way for greener cancer treatments
Scientists from The University of Manchester have uncovered a more efficient and sustainable way to make peptide-based medicines, showing promising effectiveness in combating cancers.
Peptides are comprised of small chains of amino acids, which are...
Europe’s ‘disappearing’ generic medicines are a growing crisis
Europe’s critical medicine cabinets – in hospitals, pharmacies, and homes – are home to fewer generic medicines. These are the often-cheaper alternatives to brand name medicines, that make up 67%1 of all medicines.
Research from Teva...
New drugs partnership tackles lung disease
Aston University scientists are working with start-up company, Isterian Biotech, part of Cambrian BioPharma, to develop novel drugs to treat fibrotic diseases such as lung disease.
The focus of preclinical-stage biotechnology company Isterian Biotech is...
Cellular ‘traffic controllers’ caught managing flow of signals from receptors
First time that individual beta-arrestin molecules are directly observed as they control receptor-mediated signals in living cells using advanced microscopy.
New findings could inform the development of better drugs for pain relief,...
Biochemical synthesis breakthrough could unlock new medicines
A mystery about lab synthesis of a natural chemical compound may have been solved – a breakthrough which could unlock new developments in medicine.
Scientists in Scotland and Germany made the discovery, published in the...
Tiny sea microbes could unlock new cures
Off the coast of Spain, studies of the marine microbiome are opening new doors for pharmacology, writes Claudia Alemañy Castilla.
The island of Tabarca, near Alicante, is a tourist magnet. It’s also a working platform...
Emerging biotechs jumpstart drug commercialisation via out-licencing – a Deloitte analysis
By Hanno Ronte, life sciences and healthcare partner at Deloitte.
Examining the various go-to-market strategies deployed by emerging biotech companies when launching their first product into Europe reveals how the frequencies of these strategies changed...
‘World-first’ immunotherapy drug designed by generative AI
British techbio innovator Etcembly has kickstarted the next generation of immunotherapies with a pipeline of best-in-class T cell receptor (TCR) therapeutics designed using generative AI.
The company’s lead therapeutic programme, ETC-101, is the world’s first...
Trailblazing scientist is first British winner of Lifetime Achievement Award
British scientist Dame Carol Robinson has received the Lifetime Achievement Award at the European Inventor Award 2024.
The Professor of Chemistry at the University of Oxford is a trailblazer in the field of mass spectrometry...
Pain killers made from pine trees instead of crude oil
Common drugs such as paracetamol and ibuprofen can be made from a chemical from pine trees instead of crude oil products.
A team of scientists, from the University of Bath’s Department of Chemistry and Institute...